Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
Journal of Drugs in Dermatology · 2026-05-01 · 25 (5) · 413-420
DOI: 10.36849/jdd.9954 ↗At a glance
Übersichtsarbeit in Journal of Drugs in Dermatology, published online on 2026-04-01. Written by Brooke Bartley and 11 co-authors. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Cutaneous Squamous Cell Carcinoma, Immune Checkpoint Inhibitors.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Bartley, B., Rosenberg, A., DeBusk, L., Farberg, A. S., Dinehart, S. M., Trotter, S. C., Ackerman, L., Groisser, D., Schlesinger, T., Rosso, J. Q. D., Lebwohl, M., & Rigel, D. (2026). Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology, 25(5), 413-420. https://doi.org/10.36849/jdd.9954
Vancouver
Bartley B, Rosenberg A, DeBusk L, Farberg AS, Dinehart SM, Trotter SC, et al. Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology. 2026;25(5):413-420. doi:10.36849/jdd.9954
BibTeX
@article{Bartley2026,
author = {Bartley, Brooke and Rosenberg, Angela and DeBusk, Lauren and Farberg, Aaron S and Dinehart, Scott M and Trotter, Shannon C and Ackerman, Lindsay and Groisser, Daniel and Schlesinger, Todd and Rosso, James Q Del and Lebwohl, Mark and Rigel, Darrell},
title = {Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel},
journal = {Journal of Drugs in Dermatology},
year = {2026},
volume = {25},
number = {5},
pages = {413--420},
doi = {10.36849/jdd.9954}
}
EUVIMED